Influence of APOE Genotype on Alzheimer’s Disease CSF Biomarkers in a Spanish Population

Table 4

CSF AD variables after clinical diagnosis at two-year follow-up.

CSF variables	Diagnosis	Number of patients	Mean ± S.D.	Significance level
Aβ protein; (pg/mL)	AD; No AD	14; 42	743.36 ± 292.64; 1170.83 ± 462.0	0.002
T-tau protein; (pg/mL)	AD; No AD	14; 42	511.21 ± 271.6; 244.71 ± 131.75	0.0001
			Median (25–75)
p-tau protein; (pg/mL)	AD; No AD	14; 42	76.0 (63.53–106.75); 41.5 (40.3–53.94)	0.0001
Ratio; T-tau/Aβ	AD; No AD	14; 42	0.83 (0.52–1.08); 0.16 (0.09–0.32)	0.0001
Ratio; p-tau/Aβ	AD; No AD	14; 42	0.11 (0.08–0.18); 0.03 (0.03–0.05)	0.0001

Student’s t-test. Mann-Whitney test.